Mektovi (binimetinib) — United Healthcare
Non-small cell lung cancer (NSCLC)
Preferred products
- Braftovi (encorafenib)
Initial criteria
- Diagnosis of non-small cell lung cancer (NSCLC)
- Disease is recurrent, advanced, or metastatic
- Patient is positive for BRAFV600 mutation
- Used in combination with Braftovi (encorafenib)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Mektovi therapy
- Used in combination with Braftovi (encorafenib)
Approval duration
12 months